Asana, Inc. (LTSE: ASAN), a leading enterprise work management platform, today announced that Dustin Moskovitz, Co-Founder, CEO and Chair of Asana, has informed the Board of Directors of his intention ...

Amneal Pharmaceuticals had a negative return on equity of 346.26% and a negative net margin of 6.88%. During the same period last year, the business earned $0.14 EPS.

“We have a longstanding and productive partnership with Amneal, and we are pleased to be advancing these two important products to the U.S. biosimilar market. We remain focused on our globalization ...

BRIDGEWATER, N.J., March 03, 2025--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal" or the "Company"), a global biopharmaceutical company, and ...

Barclays raised the firm’s price target on Amneal Pharmaceuticals (AMRX) to $11 from $10 and keeps an Overweight rating on the shares. The company’s Q4 beat, “strong” 2025 guidance and ...

In this article, we are going to take a look at where Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) stands against other best weight loss drug stocks to buy according to analysts. Most people have ...

Anthony Dimeo; Head-Investor Relations; Amneal Pharmaceuticals Inc. Chirag Patel; President, Co-Chief Executive Officer, Co-Founder, Director; Amneal Pharmaceuticals Inc. Chintu Patel; Co-Chief ...

Anthony Dimeo; Head-Investor Relations; Amneal Pharmaceuticals Inc. Chirag Patel; President, Co-Chief Executive Officer, Co-Founder, Director; Amneal Pharmaceuticals Inc. Chintu Patel; Co-Chief ...

Amneal Pharmaceuticals (NASDAQ:AMRX) Inc. reported its Q4 2024 earnings, revealing a slight miss on earnings per share (EPS) expectations, while revenue exceeded forecasts. The company’s EPS came in ...

Q4 2024 Management View Chirag Patel, Co-CEO, highlighted Amneal's "stellar financial performance" in 2024, citing double-digit revenue and adjusted EBITDA growth, reduction of net leverage below four ...